ERBB2 and breast cancer: As such, HR-positive, HER2-low BC has a distinct molecular profile than HR-negative, HER2-low BC: while the first is enriched with luminal subtypes, the latter demonstrates a predominance of the basal-like subtype, underlining major genetic, clinicopathological, and prognostic differences within the group [17].